15th Feb 2016 09:02
LONDON (Alliance News) - ImmuPharma PLC on Monday revealed that US patients have begun dosing in a Phase III clinical trial of Lupuzor, its potential treatment for autoimmune disease Lupus.
"This is the next key milestone for ImmuPharma's Lupuzor trial, and we are therefore delighted that following the initial US sites being opened, we can now confirm that the first Lupus patients have commenced dosing," Chairman Tim McCarthy said.
"With recruitment going to plan, we look forward to providing further positive updates on this Lupuzor Phase III study as it progresses throughout this year and 2017," McCarthy added.
Shares in ImmuPharma were up 1.1% at 24.65 pence on Monday morning.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma